United States Ex Rel. Downy v. Corning, Inc.United States Ex Rel. Downy v. Corning, Inc.
OPINION
THIS MATTER comes before the Court for consideration of Defendants’ motion to dismiss (Doc. 55) the fourth amended complaint filed in this case by Mary J. Downy (“Relator”). The Court has reviewed the submissions of the parties and the relevant law. For the reasons set forth below, the Court will deny the motion to dismiss.
BACKGROUND
This is a qui tam action filed under the federal False Claims Act, 31 U.S.C. §§ 3729-3733 (Supp.2000) (“FCA”). Relator originally filed a complaint under seal, as she was required to do under Section 3730(b)(2). The United States requested, and was granted, several extensions of the statutory 60-day period permitted for the government to determine whether to intervene in a qui tam case. The United States eventually decided not to intervene in the case. Meanwhile, for reasons not made clear to the Court, Defendants were served with copies of the fourth amended complaint (“Complaint”), even though the seal had not been lifted and no permission to effect such service had been granted.
Relator’s FCA claim is basically the following. Defendants operate a number of medical laboratories throughout the United States. During the period from 1988 to at least 1993, and perhaps beyond, Defendants submitted false claims for payment to several government programs, including the Medicaid and Medicare programs. Defendants did so by performing unnecessary blood tests and by inducing doctors to request unnecessary blood tests for many of their patients. The tests involved were the prostatic acid phosphatase (“PAP”) test and the prostate-specific antigen (“PSA”) test, both of which are designed to test for the presence of prostate cancer.
Defendants have moved to dismiss the Complaint with prejudice. In support of their motion, Defendants have raised a number of arguments. The Court will discuss each argument separately.
Violation of Seal Procedure by Premature Service of Complaint
As discussed above, the FCA required Relator to file her complaint under seal. The purpose of this requirement is to allow the United States an opportunity to evaluate the lawsuit and the facts underlying the suit, whether the ease is related to an ongoing criminal investigation, and whether to intervene in the suit.
See United States ex rel. Lujan v. Hughes Aircraft Co.,
As the Ninth Circuit pointed out in
Lujan,
nothing in the FCA indicates the penalty for premature service, or any other violation of the seal requirement, should be dismissal of the case.
Lujan,
p. 245. Instead, such a severe sanction should be reserved for cases involving great harm to the interests promoted by the seal provision.
Id.
Furthermore, because the aim of the provision is to protect the government’s interests, it is prejudice to the government’s interests, rather than the defendant’s, that is the primary consideration in deciding on an appropriate sanction.
Id.,
p. 247. Given the government’s decision not to intervene and to allow Relator to continue the case alone, there is little chance such prejudice occurred, and Defendants point to none.
See United States ex rel. Kusner v. Osteopathic Medical Center of Philadelphia,
Public Disclosure of Information Related to Relator’s Complaint
Defendants raise a jurisdictional argument in support of dismissal, arguing Relator’s lawsuit is based on publicly-disclosed allegations or transactions. Unless the relator is an “original source” of information, the FCA bars lawsuits that are based on the public disclosure of allegations or transactions, if such disclosure occurs in a criminal, civil, or administrative hearing, a congressional, administrative, or GAO report, hearing, audit, or investigation, or in the news media.
See
§ 3730(e)(4)(A). This restriction is jurisdictional.
See United States ex rel. Fine v. Sandia Corp.,
In determining whether the jurisdictional bar applies, several possible issues may arise, including the question of whether the relator was an original source of the information, whether the disclosure occurred in one of the specific sources listed in the FCA, whether the disclosure was made “public” within the meaning of the FCA, and whether the relator’s complaint is “based upon” the disclosed information in the manner contemplated by the FCA.
See, e.g., United States ex rel. Fine v. Advanced Sciences, Inc.,
Relator’s position with respect to this question is straightforward. She argues her claim is not “based upon” the disclosed information, within the meaning of the FCA, because the disclosures did not involve “allegations or transactions.” Instead, maintains Relator, the disclosures contained only general information concerning the PSA and PAP blood tests, and no information regarding Defendants’ alleged fraudulent practices. Defendants disagree with Relator’s characterization. To resolve the conflict, it is necessary to examine in detail the disclosures that, according to Defendants, should bar Relator’s action.
According to Defendants, in 1994 the federal government, through a contractee (“AdminaStar”), began a nationwide project designed to develop correct “coding methodologies” for the submission of claims for payment for services provided to Medicare patients. One
of the
goals of this project was to identify tests that should not be billed together. For example, AdminaStar created a list of tests thought to be mutually exclusive. If one test was performed by a laboratory, Admi-naStar proposed that payment could not be requested or made for another test deemed to be mutually exclusive. In addition, AdminaStar proposed a list of tests in which one of the tests was thought to be more complex than the other, and inclusive of the other.
1
The more complex test was
In response to AdminaStar’s proposal, several members of the public contacted AdminaStar to express concern that the PAP and PSA tests were improperly included on the most-extensive-procedures list. Their comments pointed out that PAP and PSA are different tests, serving different purposes, and that both tests might be medically necessary to identify the presence of prostate cancer. As a result of these comments, AdminaStar removed the PAP and PSA tests from the list of most extensive procedures, thereby continuing to allow billing and payment for both tests.
Defendants argue that Relator’s lawsuit is directly related to the issue of double-billing for both the PSA and PAP tests, and is therefore based upon the public disclosures discussed above. Relator, on the other hand, contends that public disclosure of this general information is not sufficient to bar her action. She points out that the issue discussed by AdminaStar was whether a medical provider should ever be allowed to bill for both the PSA and PAP tests. Her claim, on the other hand, is that Defendants effectively prevented physicians from choosing one test or the other, even when only one test was medically necessary. In addition, she argues that public knowledge or disclosures of the fact that fraud or waste is occurring in a certain area of federal spending, in general, is not the type of public disclosure contemplated by the FCA. Instead, there must be specific disclosure that a party, or a limited number of parties who would be easily identifiable, are engaged in a particular type of fraudulent activity.
Resolution of this issue depends on the standard to be used in deciding what “based upon” a “public disclosure” means under the FCA. On the one hand, the Tenth Circuit has held that the jurisdictional bar applies even where a relator’s complaint is based in any part upon publicly disclosed allegations or transactions.
United States ex rel. Precision Co. v. Koch Industries, Inc.,
The broad interpretation of
Springfield Terminal
has been adopted by several other Circuits.
See United States ex rel. Jones v. Horizon Healthcare Corp.,
In
United States ex rel. Fine v. Advanced Sciences, Inc.,
It is apparent that in the Tenth Circuit cases, a particular alleged wrongdoer had been identified in the public disclosures or would be readily identifiable given the information in those disclosures, and a specific explanation of the alleged wrongdoing had been provided. This satisfies the Springfield Terminal standard’s requirement that either an allegation of fraud have been made publicly, or the elements of the fraud claim have been made public. In the case before the Court, however, the only information made public was a debate about whether laboratories should ever be able to charge for both a PAP test and a PSA test. Furthermore, the debate centered around the question of whether the PAP test was included in the supposedly more complex PSA test, not whether the PAP test’s efficacy was in question or double-testing encouraged. No allegation of wrongdoing was made during the public discussion; the only question was what testing policy should be adopted in the future, not whether fraud was involved in past billing practices. Finally, no particular party was identified as having engaged in the practice of inappropriate billing for both a PAP and PSA test, and there has been no showing that the number of laboratories submitting claims for such tests was so small that it would be a simple matter to identify the laboratories that might be engaged in the practice.
Relator’s Complaint, on the other hand, specifically identifies Defendants as having
Separation of Powers Issue
Defendants maintain that allowing Relator to proceed with this lawsuit, even though the government has declined to intervene, violates Article II, § 3 of the United States Constitution, the Take Care Clause. 2 Defendants’ argument is that the executive branch of the federal government is responsible for investigating and prosecuting alleged violations of federal law; that Congress, through the FCA, has impermissibly encroached on the executive branch’s powers; and that the FCA’s qui tam provisions are therefore unconstitutional to the extent they allow a relator to proceed with a lawsuit in the absence of intervention by the government.
This question has been exhaustively discussed in two different Circuit opinions.
3
In the first,
United States ex rel. Kelly v. Boeing Co.,
Statute of Limitations
Length of Limitations Period: Defendants have raised several issues concerning the statute of limitations applicable to this case. The most significant of these issues is the question of whether the limitations period should be six years, ten years, or some period in between. The issue arises because the FCA provides that no civil action may be brought: “(1) more than 6 years after the date on which [a violation] is committed, or (2) more than 3 years after the date when facts material to the right of action are known or reasonably should have been known by the official of the United States charged with responsibility to act in the circumstances, but in no event more than 10 years after the date on which the violation is committed, whichever occurs last.” 31 U.S.C. § 3731(b). Defendants maintain the six-year period of subsection (1) applies to this ease, since the government has declined to intervene and the three-year tolling provision of subsection (2) may only be taken advantage of by the government. Plaintiff contends the tolling provision applies to actions prosecuted solely by private rela-tors as well as to actions in which the government has intervened. She also contends the government first obtained knowledge of the false claims when she filed her original complaint, and her action is therefore timely as to all violations occurring ten years prior to 1996, the year she filed that complaint.
A few courts have considered the question of whether a private relator is entitled to take advantage of the three-year tolling provision of Section 3731(b)(2). Unfortunately these courts have not been uniform in their responses. In fact, three different approaches to the issue have been formulated. Two district courts have held that the three-year tolling provision applies only if the government has intervened in the action.
See United States ex rel. Amin v. George Washington Univ.,
In contrast to the
Amin
and
Thistleth-waite
approach, the Ninth Circuit and at least one district court have held that a relator is placed in the same position as the United States with respect to the tolling provision. That is, the three-year limitations period found in Section 3731(b)(2) begins to run when the relator has knowledge, or should have knowledge, of the facts concerning the FCA violation.
See United States ex rel. Hyatt v. Northrop Corp.,
Finally, one district court has adopted a position, based on the literal language of Section 3731, which is the most favorable to relators. In
United States ex rel. Colunga v. Hercules Inc.,
In the Court’s view, each.of these three approaches has some logical appeal, each has certain benefits, and each has practical drawbacks. The
Thistlethwaite/Amin
approach has the advantage of relying on the plain language of the statute. However, this approach’s insistence that only an “official of the United States” may take advantage of the tolling provision ignores the structure of the FCA, which often refers only to the United States when it is obvious Congress intended the reference to include relators. Furthermore, the legislative history discussed in
Hyatt
and
Bida-ni,
and examined by this Court, makes clear that the Congressional intent behind the tolling provision is to ensure the government’s rights are not lost through successful deception on the part of the FCA defendant. This intent is no different
The Hyatt/Bidani approach, substituting the relator for the United States, is consistent with the structure of the FCA as reflected in other provisions. In addition, as these cases discuss, this approach prevents a relator from in effect setting her own statute of limitations. If a relator’s knowledge of the violation is irrelevant, the relator can simply bide her time, letting the false claims pile up (assuming there is an ongoing practice of submitting such claims), and then notify the government (by filing suit) at the last possible moment. 7 One drawback to this approach, however, is that it still forces the government to intervene to protect its rights, where the relator has waited more than three years following notice of the violation to bring suit.
The
Colunga
approach also relies on the literal language of the statute, ignoring the fact that “United States” also often includes “relator” in the statutory scheme.
See Koch,
After considering all of the above factors, the Court will adopt the Hyatt/Bida-ni approach to this question. Although the Congressional intent with respect to private relators is not always entirely clear in the FCA, due to the omission of any mention of relators in many parts of the statute, it is apparent that for the most part Congress intended relators to be on the same procedural footing as the United States. Also, as mentioned above, it does not seem correct to pick and choose the times when “relator” will or will not be substituted for “United States” in the statute. Finally, the Court agrees that Congress most likely did not intend to allow relators to sit back indefinitely and allow false claims to accumulate, acting only in time to avoid the ten-year statute of repose.
In this case, no evidence has been presented as to when Relator first learned of Defendants’ alleged false claims. No decision will be made at this time, therefore, as to the effect, if any, the three-year tolling provision discussed above will have on the litigation.
When the Case Commences for Statute-of-Limitations Purposes: Defendants raise a novel argument, con
Critical examination of Defendants’ argument leads to the conclusion that it is contrary to the language, structure, and purposes of the FCA. In Section 3730, referring to actions by private persons, the statute states that a person may “bring a civil action” for violation of the FCA. Section 3730 then continues with the provisions regarding service of the complaint on the government, sealing the complaint for sixty days (plus extensions), and other procedural matters. Then, in Section 3731, the statute provides that “a civil action under section 3730 may not be brought” after the periods of time set out in the Section. It is apparent that the limitations provisions of Section 3731 are referring to the relator’s initial act of filing the civil action, not to the later date when the complaint is unsealed. Furthermore, Defendants’ argument, if adopted, would pressure the government to act immediately to decide whether to intervene in a relator’s lawsuit, rather than requesting extensions of the sixty-day period for such decision, as allowed by Sections 3730(b)(2) and (3). While this may be a preferable policy choice for defendants in an FCA case, nothing in the statute or in the legislative history indicates Congress intended such a result. In addition, Defendants’ argument is unfair to relators, who can object to an extension requested by the government but have no power to prevent it from being granted; under Defendants’ argument, each time an extension is granted to the government more potential false-claim recoveries recede behind the barrier of the continuously-moving limitations period. Finally, Defendants’ interpretation runs contrary to established federal law, which holds a case is initiated (and the statute of limitations tolled) when the complaint is filed.
See, e.g., Gilles v. United States,
Defendants’ constitutional arguments are similarly without merit under existing law. Furthermore, Defendants have not mustered the type of authority or argument that would warrant the drastic action of declaring the FCA unconstitutional. For example, Defendants argue that as long as the complaint remains sealed they are deprived of due process, because they have no opportunity to investigate the claims, unless the action is construed to begin on the date of unsealing. Defendants cite scant authority for this proposition. The Court notes that criminal actions often remain sealed, while the target of the criminal action remains unaware of his status as a target.
See, e.g., United States v. Bracy,
Defendants make a cursory argument to the effect that Relator’s claims are stale and must therefore be dismissed. Without actual evidence of such staleness, rather than mere argument, the Court has no basis for such dismissal. In sum, the Court will not adopt Defendants’ construction of the FCA limitation-of-action provision, and denies the motion to dismiss on statute-of-limitations grounds.
Failure to Plead Fraud With Particularity
Defendants maintain, and Relator does not contest, that the pleading-fraud-with-particularity requirement of Rule 9(b) applies to FCA
qui tam
actions. Fed.R.Civ.P. 9(b);
see United States ex rel. Pogue v. American Healthcorp., Inc.,
Relator’s Complaint names as Defendants Corning, Inc., Corning Clinical Laboratories, Inc., Corning Life Sciences, Inc., Metpath Corning Clinical Labs, Inc., and Metpath, Inc. The Complaint alleges that certain of these Defendants operate laboratories around the country, and that certain other Defendants are parent corporations of the other Defendants. The Complaint further alleges the Defendants engaged in the pattern and practice of fraudulent activity described above — -by using deceptive test order forms and by disseminating deceptive information concerning the necessity of performing both the PSA and PAP tests, Defendants induced physicians to order many medically unnecessary tests and then charged the costs of those tests to the government.
Defendants argue the Complaint is deficient under Rule 9(b) for several reasons. First, they maintain it does not specify, which Defendant did what, and instead lumps all Defendants together in conclusory fashion, alleging “Defendants” submitted false claims to the government. Second, they point out the Complaint does not identify a single instance in which a false claim was actually submitted to the United States for payment, relying instead on the general allegations concerning the allegedly fraudulent scheme. Finally, they maintain the Complaint does not specify a time frame as to when the supposed false claims were submitted for payment, and instead avers a general time frame from 1988 to 1993.
Relator incorporated a number of documents into her Complaint. These documents are, for the most part, test order forms published and allegedly disseminated by Metpath Corning, Metpath Incorporated, and Metpath as a Corning Clinical Laboratory. The Complaint, therefore, adequately identifies these Defendants as the entities alleged to have used deceptive test order forms to further Defendants’ submissions of false claims. In addition, as to Corning, Inc., Corning Life Sciences, Inc., and Corning Clinical Laboratories, the Complaint maintains they are parent corporations of Metpath and other Defendant laboratory companies, and claims they are liable for the actions of their subsidiaries. As to these Defendants also, therefore, the Complaint sufficiently alleges the basis of Relator’s claim that they are liable for the alleged false claims submitted to the government. 8
Relator’s Complaint in this case appears similar to the complaint in
Pogue.
The Complaint adequately describes an allegedly fraudulent scheme, resulting in the submission of false claims for unnecessary medical tests. By attaching the test requisition forms to the Complaint, each of which contains only one blank to check for “PSA/PAP” tests, Relator adequately alleged the general mechanics of the scheme. However, Relator failed to provide a single example of an instance in which a physician was induced to request an unnecessary PAP test, as a result of the test requisition forms or Defendants’ representations concerning the PAP test. The Court notes some form of limited discovery would probably be necessary to allow Relator to provide such specific examples, if they exist, since information concerning the physicians who requested PSA/PAP tests from Defendants’ laboratories is undoubtedly in Defendants’ possession rather than the public domain.
See United States v. NHC Healthcare,
CONCLUSION
Based on the foregoing discussion, Defendants’ motion to dismiss will be denied.
ORDER
A Memorandum Opinion having been entered this date, it is hereby ORDERED as follows: Defendants’ motion to dismiss (Doc. 55) is DENIED.
Notes
. It is helpful to think of the question in criminal law terms — the less complex lest would be analogous to a lesser included offense, entirely included within the more complex test. Similarly, in mathematical terms, the less complex test would be a subset of the more complex test, and entirely included within the more complex test.
. Defendants originally raised a challenge to Relator’s standing as a
qui tam
plaintiff, but that issue has been decided adversely to Defendants by the Supreme Court.
See Vermont Agency of Natural Resources v. United States ex rel. Stevens,
. The separation-of-powers aspect of qui tam has also sparked extensive analysis by the academic community. See Evan Caminker, The Constitutionality of Qui Tam Actions, 99 Yale L.J. 341 (1989); Sean Hamer, Lincoln’s Law: Constitutional and Policy Issues Posed by the Qui Tam provisions of the False Claims Act, 6 Kan.J.L. & Pub. Policy 89 (1997); James T. Blanch, Note, The Constitutionality of the False Claims Act’s Qui Tam Provision, 16 Harv.J.L. & Pub. Policy 701 (1993); Frank A. Edgar, Jr., Comment, "Missing the Analytical Boat”: The Unconstitutionality of the Qui Tam Provisions of the False Claims Act, 27 Idaho L.Rev. 319 (1990); Robert E. Johnston, Note, 1001 Attorneys General: Executive-Employee Qui Tam Suits and the Constitution, 62 Geo.Wash .L.Rev. 609 (1994); Thomas R. Lee, Comment, The Standing of Qui Tam Relators Under the False Claims Act, 57 U.Chi.L.Rev. 543 (1990); Ara Lovitt, Note, Fight for Your Right to Litigate: Qui Tam, Article II, and the President, 49 Stan.L.Rev. 853 (1997); John P. Robertson, Comment, The False Claims Act, 26 Ariz.St.L.J. 899 (1994).
.The
qui tam
provisions were also found constitutional by the Sixth Circuit, in a brief discussion contained in
United States ex rel. Taxpayers Against Fraud v. General Electric Co.,
. For this reason, the Court denies Defendants' request for supplemental briefing on this issue.
. It is important to remember that even when a relator proceeds alone, the United States still receives the lion's share of any recovery gained from the action, with the relator’s share limited to no more than thirty percent of the recovery. 31 U.S.C. § 3730(d)(2).
. Of course, a relator who follows such a practice risks losing the claims entirely, because if the false claims come to light through a public disclosure, the relator will lose the ability to bring a qui tam lawsuit under the FCA. See discussion above concerning jurisdictional public-disclosure bar.
. Defendants have not made any argument concerning parent/subsidiary liability in this case, and the Court expresses no opinion as to whether the Complaint alleges sufficient facts to state such a claim.